Saphnelo (anifrolumab-fnia) is a prescription drug used to treat systemic lupus erythematosus (SLE). It is given as an intravenous (IV) infusion by a healthcare professional. Saphnelo is used to ...

Saphnelo will compete in the market most closely with GlaxoSmithKline's BLyS inhibitor Benlysta (belimumab), which has been available in the EU to treat SLE since 2011 and recorded worldwide sales ...

When cutaneous features such as malar rash, discoid lesions, and photosensitivity are present, rheumatologists are more likely to turn to biologics, most notably AstraZeneca’s Saphnelo ...

These include GSK’s Benlysta (belimumab) and AstraZeneca’s Saphnelo (anifrolumab). The market for CLE, however, has seen even less innovation. CLE is a form of lupus that primarily affects the ...

and AstraZeneca’s Saphnelo (anifrolumab), specifically for SLE in over 50 years. The latest Phase III data for Gazyva is ...

When cutaneous features such as malar rash, discoid lesions, and photosensitivity are present, rheumatologists are more likely to turn to biologics, most notably AstraZeneca’s Saphnelo (anifrolumab), ...